2024 ESC Guidelines for the Management of Atrial Fibrillation

Authors, Journal, Affiliations, Type, DOI

• Chairpersons: Isabelle C. Van Gelder (Netherlands), Dipak Kotecha (United Kingdom)
• Task Force Co-ordinators: Michiel Rienstra, Karina V. Bunting
• Multi-national ESC Task Force with contributions from EACTS, EHRA, ESO
• Journal: European Heart Journal, 2024; 45:3314–3414
• Type: Clinical Practice Guideline
• DOI: https://doi.org/10.1093/eurheartj/ehae176

Overview

The 2024 ESC Guidelines replace the 2020 ABC pathway with the AF-CARE framework ([C] Comorbidity and risk factor management, [A] Avoid stroke and thromboembolism, [R] Reduce symptoms by rate and rhythm control, [E] Evaluation and dynamic reassessment), placing comorbidity management as the first and foundational pillar applicable to all patients. Major upgrades include catheter ablation elevated to Class I/Level A for first-line treatment of paroxysmal AF, adoption of the CHA2DS2-VA score (removing sex category), SGLT2 inhibitors becoming Class I for AF patients with heart failure regardless of ejection fraction, and surgical LAA closure upgraded to Class I/B (driven by the LAAOS III trial). The guideline strongly emphasizes early rhythm control within 12 months of diagnosis in selected patients and mandates dynamic, individualized reassessment for all patients.

Keywords

Guidelines • Atrial fibrillation • AF-CARE • Comorbidity • Risk factors • Anticoagulation • Rate control • Rhythm control • Cardioversion • Antiarrhythmic drugs • Catheter ablation • AF surgery • Evaluation • Stroke • Thromboembolism

Key Takeaways

Section 3 — Definitions and Classification

• Temporal classification (retained from prior guidelines): first-diagnosed, paroxysmal (self-terminating ≤7 days), persistent (non-self-terminating), long-standing persistent (≥12 months), permanent (shared decision to accept AF)
• Clinical AF requires ECG confirmation (12-lead, single, or multiple leads) ≥30 s to initiate management — Class I/A
• Device-detected subclinical AF (AHRE ≥5 min, atrial rate ≥170 bpm on implanted devices or wearables): a predictor of future clinical AF (6–9% per year); requires visual inspection to exclude artefacts
• Atrial cardiomyopathy concept introduced: structural, electrical, or functional atrial changes leading to AF progression, treatment failure, or heart failure
• Adverse outcomes: AF carries 4–5× risk of heart failure, 2.3× risk of ischaemic stroke, and 2× risk of all-cause mortality; also linked to cognitive impairment and vascular dementia

Section 4 — AF-CARE Principles

• AF-CARE replaces the 2020 ABC pathway; reorganized to emphasize that comorbidity management [C] underpins the success of all other treatment pillars
• Patient-centred, multidisciplinary approach is recommended (Class IIa/B); equality of care across gender, ethnicity, socioeconomic status is Class I/C
• Shared decision-making is central; patient education, family/caregiver education, and healthcare professional education all recommended Class I/C
• Patient pathways exist for: first-diagnosed AF, paroxysmal AF, persistent AF, and permanent AF (Figures 4–7 in guideline)

Section 5 — [C] Comorbidity and Risk Factor Management

• Hypertension: Blood pressure-lowering treatment Class I/B; target 120–129/70–79 mmHg
• Heart failure: Diuretics for congestion Class I/C; appropriate HF medical therapy (for reduced LVEF) Class I/B; SGLT2 inhibitors Class I/A regardless of ejection fraction (reduces HF hospitalization and cardiovascular death)
• Diabetes: Effective glycaemic control Class I/C; metformin or SGLT2 inhibitors IIa/B for prevention of AF
• Obesity: Weight loss ≥10% target Class I/B (upgraded from IIa); bariatric surgery IIb/C if BMI ≥40 (or ≥35 with complications) when rhythm control planned
• Obstructive sleep apnoea: Management IIb/B (may reduce recurrence); symptom-only screening questionnaires not recommended (Class III/B)
• Physical activity: Tailored exercise programme Class I/B for paroxysmal/persistent AF; 150–300 min/week moderate or 75–150 min/week vigorous activity for AF prevention
• Alcohol: Reduce to ≤3 standard drinks/week (≤30 g alcohol) Class I/B; avoidance of binge drinking Class I/B for prevention

Section 6 — [A] Avoid Stroke and Thromboembolism

Thromboembolic Risk Assessment

• CHA2DS2-VA score adopted (sex category removed from CHA2DS2-VASc): Score ≥2 = OAC recommended (Class I/C); Score 1 = OAC should be considered (Class IIa/C)
• OAC recommended in all AF patients with hypertrophic cardiomyopathy or cardiac amyloidosis regardless of CHA2DS2-VA score (Class I/B)
• Periodic individualized reassessment of thromboembolic risk recommended (Class I/B)
• Temporal pattern of AF (paroxysmal vs. persistent) is not relevant to OAC decisions (Class III)

Direct Oral Anticoagulants

• DOACs preferred over VKAs in eligible patients (Class I/A); 50% reduction in intracranial haemorrhage vs. warfarin; non-inferior or superior efficacy for stroke/SE prevention
• Reduced-dose DOACs should only be used if patient meets specific dose-reduction criteria (Class III/B against underdosing)
• DOACs contraindicated in mechanical heart valves and moderate-to-severe mitral stenosis; safe for bioprosthetic valves and TAVI
• Device-detected subclinical AF: DOAC may be considered (Class IIb/B) in high stroke risk + absence of major bleeding risk (based on ARTESiA trial showing HR 0.63 for stroke/SE with apixaban vs. aspirin, but higher major bleeding HR 1.36)

Vitamin K Antagonists

• VKA target INR 2.0–3.0; keep TTR >70% (Class IIa/A)
• Switch VKA → DOAC recommended if TTR <70% (Class I/B)
• In patients ≥75 years on stable VKA with polypharmacy: may consider maintaining VKA rather than switching (Class IIb/B), based on higher bleeding with switching in this subgroup

Antiplatelet Therapy

• Adding antiplatelet to OAC NOT recommended for stroke/SE prevention (Class III/B)
• Antiplatelets NOT recommended to prevent recurrent embolic stroke in OAC-treated patients (Class III/B)
• Routine switching between DOACs without clear indication not recommended (Class III/B)

Left Atrial Appendage Occlusion

• Surgical LAA closure during cardiac surgery: Recommended (Class I/B) as adjunct to OAC — based on LAAOS III (HR 0.67 for ischaemic stroke/SE over 3.8 years)
• Surgical LAA closure during endoscopic/hybrid ablation: Class IIa/C
• Stand-alone epicardial LAA closure (contraindication to OAC): Class IIb/C
• Percutaneous LAAO (Watchman, Amulet): Class IIb/C for patients with contraindications to all OAC options; awaiting larger RCTs

Bleeding Risk

• Assess and manage all modifiable bleeding risk factors (Class I/B); do not use bleeding risk scores to withhold OAC (Class III/B)
• Specific DOAC antidotes (idarucizumab for dabigatran; andexanet alfa for factor Xa inhibitors) recommended to consider for life-threatening bleed (Class IIa/B)

Section 7 — [R] Reduce Symptoms by Rate and Rhythm Control

Rate Control

• Rate control therapy recommended as initial treatment in acute setting, adjunct to rhythm control, or sole strategy (Class I/B)
• Target: resting HR <110 bpm (lenient control); stricter if symptoms persist
• LVEF >40%: Beta-blockers, digoxin, diltiazem, or verapamil (Class I/B)
• LVEF ≤40%: Beta-blockers or digoxin only (Class I); avoid diltiazem/verapamil
• Amiodarone: last resort for rate control only; significant extracardiac toxicity
• AVN ablation + CRT (ablate and pace): Class IIa/B in severely symptomatic permanent AF patients with ≥1 HF hospitalization (APAF-CRT trial)

Rhythm Control — Cardioversion

• Electrical cardioversion recommended for haemodynamic instability (Class I/C)
• DOACs preferred over VKAs for cardioversion (Class I/A)
• Therapeutic OAC ≥3 weeks before scheduled cardioversion (Class I/B); or TOE to exclude thrombus (Class I/B)
• Early cardioversion not recommended without OAC ≥3 weeks or TOE if AF duration >24 h (Class III/C)
• Wait-and-see approach (spontaneous conversion within 48 h) should be considered in haemodynamically stable patients (Class IIa/B) — RACE 7 ACWAS trial
• OAC ≥4 weeks post-cardioversion for all; long-term if any thromboembolic risk factor (Class I/B)

Rhythm Control — Antiarrhythmic Drugs

• Drug choice depends on structural heart disease:
  • No/minimal SHD: Dronedarone, flecainide, propafenone, sotalol (IIb), amiodarone
  • HFrEF (LVEF ≤40%): Amiodarone only
  • HFmrEF (LVEF 41–49%) / CAD / valvular HD: Amiodarone or dronedarone
• AADs not recommended in advanced conduction disease without antibradycardia pacing (Class III/C)
• EAST-AFNET 4: Early rhythm control (within 12 months) vs. usual care — significantly reduced CV death/stroke/HF hospitalisation/ACS (mainly via AADs in 80% of intervention arm)

Rhythm Control — Catheter Ablation

• Paroxysmal AF: Catheter ablation Class I/A as first-line within shared decision-making rhythm control strategy (upgraded from IIa/B in 2020)
• Persistent AF: Catheter ablation Class I/B after failed AAD; Class IIb/B for catheter ablation if rhythm control desired and no prior AAD trial
• HFrEF: Catheter ablation Class I if high probability of tachycardia-induced cardiomyopathy; Class IIa in selected patients (CASTLE-AF, CASTLE-HTx)
• Repeat catheter ablation: Class IIa/B if recurrence after initial ablation with symptom improvement
• AF ablation for bradycardia/sinus pauses at AF termination: Class IIa/C (to avoid pacemaker)
• Uninterrupted OAC during ablation: Class I/A

Rhythm Control — Endoscopic/Hybrid/Surgical Ablation

• Endoscopic/hybrid ablation for persistent AF refractory to AAD: Class IIa/A
• Endoscopic/hybrid ablation for paroxysmal AF failed percutaneous ablation: Class IIb/B
• Concomitant surgical ablation during mitral valve surgery: Class I/A (upgraded from IIa)
• Concomitant surgical ablation during non-mitral valve cardiac surgery: Class IIa/B
• All endoscopic/hybrid procedures: require experienced team and shared decision-making

Section 8 — [E] Evaluation and Dynamic Reassessment

• Re-evaluate at 6 months after initial presentation, then at least annually or per clinical need
• Routine ECG, blood tests, symptom assessment, thromboembolism risk reassessment (all Class I)
• TTE recommended when it will guide treatment decisions (Class I/C); valuable across all AF-CARE domains
• Patient-reported outcome measures (PROMs): AFEQT or AFSS recommended (ICHOM); underutilized clinically

Section 9 — AF-CARE in Specific Settings

• ACS/PCI: Triple therapy (OAC + DAPT) ≤1 week; then OAC + P2Y12 for up to 12 months; clopidogrel preferred P2Y12; DOACs preferred over VKA; no antiplatelet beyond 12 months in stable CCS (Class III/B)
• Post-operative AF: Long-term OAC should be considered (Class IIa/B); peri-operative amiodarone Class I/A to prevent POAF after cardiac surgery
• Pregnancy: Specific management needed; most DOACs contraindicated in pregnancy
• Older/frail patients: OAC benefit preserved; cautious individualization; VKA may be maintained if stable with polypharmacy (age ≥75, Class IIb/B)
• Atrial flutter: Managed analogously to AF for comorbidities and OAC; CTI ablation first-line for typical AFL (superior to AADs); long-term monitoring for AF development (50–70% over follow-up); OAC recommended if elevated thromboembolic risk (Class I/B)
• Congenital heart disease: OAC recommended (Class IIa/C) with AF and intracardiac repair, cyanosis, Fontan, or systemic RV
• ESUS: OAC not recommended without documented AF (Class III/A)

Section 10 — Screening and Prevention

• Screening: ECG-based methods only for diagnosis; physician review required (Class I/B); PPG/non-ECG devices not diagnostic
• Population-based screening recommended (Class IIa/B) in: ≥75 years; or ≥65 years with additional CHA2DS2-VA risk factors; using prolonged non-invasive ECG-based approach
• Smartwatches/fitness bands may be useful for detection; clinical evidence limited
• Primary prevention: Optimal BP (ACEi/ARB first-line), Class I/B; HF therapy in HFrEF Class I/B; normal weight (BMI 20–25) Class I/B; active lifestyle 150–300 min/week moderate exercise Class I/B; no binge drinking Class I/B
• SGLT2 inhibitors/metformin for DM prevention of AF: Class IIa/B
• Weight reduction in obese for AF prevention: Class IIa/B
• Extreme endurance exercise increases AF risk (2.5× vs. non-athletes)

Limitations of the Document

• Guidelines based on current available evidence; cannot cover all clinical scenarios
• Many specific patient populations underrepresented in RCTs (elderly/frail, severe CKD, liver impairment, cancer, pregnancy)
• Temporal classification of AF retained for clinical utility, but does not reflect underlying pathophysiology
• Evidence for subclinical device-detected AF anticoagulation remains uncertain; ARTESiA and NOAH gave conflicting results
• Optimal catheter ablation strategy and technique for persistent AF remain unknown
• Evidence gaps persist for: optimal OAC restart timing after ICH, LAAO post-procedural antithrombotic management, benefit of screening-detected AF treatment
• The definition of 30 seconds for clinical AF on ambulatory monitoring lacks validation against outcomes

Key Concepts Mentioned

• concepts/AF-CARE — central management framework introduced in 2024
• concepts/CHA2DS2-VA — updated thromboembolic risk score (sex category removed)
• concepts/Catheter-Ablation-AF — role and evidence for catheter ablation in AF

Key Entities Mentioned

• entities/Atrial-Fibrillation — primary subject of the guideline
• entities/Atrial-Flutter — managed analogously; CTI ablation first-line

Wiki Pages Updated

• wiki/sources/AF-ESC-2024.md (created)
• wiki/concepts/AF-CARE.md (created)
• wiki/concepts/CHA2DS2-VA.md (created)
• wiki/concepts/Catheter-Ablation-AF.md (created)
• wiki/entities/Atrial-Fibrillation.md (updated)
• wiki/entities/Atrial-Flutter.md (created)
• wiki/index.md (updated)
• wiki/log.md (updated)